AUPH · Aurinia Pharmaceuticals Inc
$15.35
-1.71% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
7.1
Forward P/E
13.8
Dividend yield
—
Beta
1.42
Avg volume
1M
Employees
0K
2D change
-0.85%
5D change
-0.13%
10D change
-4.64%
30D change
-11.67%
60D change
-0.72%
MTD change
-3.67%
YTD change
-4.58%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AUPH
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2025-12-03
Latest call per bank · past 12 months
Jefferies
Buy$21.00
+36.8% vs priceRBC Capital
Sector Perform$15.00
-2.3% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2025-12-03 | Leerink Partners | Downgrade | Outperform → Market Perform | $15.00 → $16.00 |
| 2025-11-07 | Jefferies | Upgrade | Hold → Buy | $10.00 → $21.00 |
| 2025-11-05 | RBC Capital | Downgrade | Outperform → Sector Perform | $9.00 → $15.00 |
| 2025-08-01 | RBC Capital | Maintains | Outperform | $8.00 → $9.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 39 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.3% below the 50-day MA ($15.96).
- Price vs 200-day MA: Trading 0.9% below the 200-day MA ($15.10).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.11) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($8.89) and high ($18.62).
AUPH Price Chart
Loading chart for AUPH…
Fundamentals
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.